SBIR/STTR Research Award

SBIR Phase I: Dense Nanolipid Fluids (DNLFs) for Delivery of Drugs with Poor Bioavailability: Synthesis, Manufacture, and Drug Properties

Award identifier 0036c789d0ff176e6ff94d45a66efb18dd9ac6e8322c8ea90b66c6b673ca6fa1Awarding agency National Science Foundation

Award amount

$256,000

Program and phase

SBIR · Phase I

Award year

2022

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
National Science Foundation
Branch
Not reported
Recipient company
SUPERIOR NANO LLC
Proposal award date
2022-06-15
Contract end date
2023-05-31
UEI
J1A3A7S6J4H7
Solicitation number
NSF 21-562
Topic code
PT

Research abstract

The broader impact /commercial potential of this Small Business Innovation Research (SBIR) Phase I project is to care for patients suffering from diseases including diabetes, multiple Sclerosis (MS), acquired immunodeficiency syndrome (AIDS), and cancer using nano dosage forms of drug molecules. Making drugs nano-sized helps them be absorbed and move to parts of the body where needed. The ability to manufacture nanosized drugs comes from the discovery that drug sizes may be decreased with a twin screw extruder, a type of machine usually used to produce bulk products such as plastic pipes, garbage bags, snack foods, cereal, and pasta. Before the discovery of the twin screw extruder, drug nanoparticles were only made in thimbleful quantities and were prohibitively expensive. This NSF SBIR Phase I project seeks to tap the potential of nano-sized drug forms by allowing them to be made economically and getting them into the hands of medical researchers. This Small Business Innovation Research (SBIR) Phase I project seeks to provide new knowledge related to surfactant-lipid-water systems and drug delivery nanoparticles. Although there has been much research focused on increasing the body’s absorption of drugs using lipid nanoparticles, translation to the clinic has been limited because nanoparticles cannot be produced with sufficient reproducibility, quality, or in sufficient quantities, making them prohibitively expensive. This SBIR project seeks to solve these problems by using twin-screw extrusion, a process typically used for bulk manufacturing of commodity goods such as plastic pipes, garbage bags, snack foods and pasta. The twin screw extruder process is based on the transient formation of rupturable surfactant-lipid-water mesophases during transit through the extruder barrel. To be successful at the twin screw extrusion of drug nano dosage forms, new scientific knowledge must be created to advance conceptualization of surfactant-lipid-water systems from time invariant equilibrium structures to highly time dependent dynamic non-equilibrium processes.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Research funding history

2 SBIR/STTR records share this UEI (2022–2025). Reported award amounts total $1,503,672. Reported amounts are not federal obligations.

Phases: Phase II, Phase I

Agencies: National Science Foundation

Agency intelligence

National Science Foundation

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.